araag2/HINT huggingface dataset:
Clinical trial NCT03046446 (phase 3, status: completed)
Conditions: osteoarthritis of the knee
ICD codes: M15.4, M15.0, M16.9, M17.9, M19.011, M19.012, M19.019
Drugs: fx006 32 mg
SMILES: OC(=O)C1=CC2=C(C=C1)N=C(O2)C1=CC(Cl)=CC(Cl)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Written consent to participate in the study

          -  Willingness and ability to comply with the study procedures and visit schedules and
             ability to follow verbal and written instructions

          -  Male or female ≥ 40 years of age

          -  Symptoms associated with OA of the index knee for ≥ 6 months prior to Screening

          -  Currently meets American College of Rheumatology (ACR) Criteria (clinical and
             radiological) for OA

          -  Kellgren-Lawrence (KL) Grade 2, 3 or 4 in the index knee based on X-ray performed
             during Screening

          -  Qualifying score for WOMAC A at Screening and Day 1/Baseline

          -  Index knee pain for >15 days over the last month (as reported by the patient)

          -  Body mass index (BMI) ≤ 40 kg/m2

          -  Ambulatory and in good general health

          -  Willingness to abstain from use of protocol-restricted medications during the study

        Exclusion Criteria:

          -  Reactive arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis,
             or arthritis associated with inflammatory bowel disease

          -  History of infection in the index knee joint

          -  Clinical signs and symptoms of active knee infection or crystal disease of the index
             knee within 1 month of Screening

          -  Presence of surgical hardware or other foreign body in the index knee

          -  Unstable index knee joint (such as a torn anterior cruciate ligament) within 12 months
             of Screening

          -  IA corticosteroid (investigational or marketed) in index knee within 3 months of
             Screening

          -  IA hyaluronic acid (investigational or marketed) in the index knee within 6 months of
             Screening

          -  IV or intramuscular (IM) corticosteroids (investigational or marketed) within 3 months
             of Screening

          -  Oral corticosteroids (investigational or marketed) within 1 month of Screening

          -  Any other IA drug/biologic use within 6 months of Screening or 5 half-lives (whichever
             is longer) (e.g., platelet rich plasma (PRP) injection, stem cells, prolotherapy and
             amniotic fluid injection)

          -  Prior administration of FX006

          -  Women of child-bearing potential not using effective contraception or who are pregnant
             or nursing
Clinical trial NCT03049735 (phase 3, status: completed)
Conditions: heavy menstrual bleeding, uterine fibroid
ICD codes: G43.831, G43.839, G43.821, G43.829, N94.9, N94.89
Drugs: relugolix, estradiol/norethindrone acetate, estradiol/norethindrone acetate placebo, relugolix placebo
SMILES: CONC(=O)NC1=CC=C(C=C1)C1=C(CN(C)C)C2=C(S1)N(CC1=C(F)C=CC=C1F)C(=O)N(C2=O)C1=CC=C(OC)N=N1, [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3, CC(O)=O, CONC(=O)NC1=CC=C(C=C1)C1=C(CN(C)C)C2=C(S1)N(CC1=C(F)C=CC=C1F)C(=O)N(C2=O)C1=CC=C(OC)N=N1
Eligibility criteria:

        Key Inclusion Criteria:

          1. Premenopausal female aged 18 to 50 years old (inclusive) on the day of signing and
             dating the informed consent form.

          2. Has regularly occurring menstrual periods of ≤ 14 days duration with a cycle of 21 to
             38 days from the start of 1 menstrual period until the start of the next, by
             participant history for at least 3 months prior to the first screening visit.

          3. Has a diagnosis of uterine fibroids that is confirmed by a transvaginal and/or
             transabdominal ultrasound performed during the screening period.

          4. Has heavy menstrual bleeding associated with uterine fibroids as evidenced by an MBL
             of ≥ 160 milliliter (mL) during 1 cycle or ≥ 80 mL per cycle for 2 menstrual cycles as
             measured by the alkaline hematin method during the screening period.

        Key Exclusion Criteria:

          1. Has transvaginal and/or transabdominal ultrasound during the screening period
             demonstrating pathology other than uterine fibroids that could be responsible for or
             contributing to the patient's heavy menstrual bleeding.

          2. Has known rapidly enlarging uterine fibroids in the opinion of the investigator.

          3. Has a weight that exceeds the weight limit of the DXA scanner or has a condition that
             precludes an adequate DXA measurement at the lumbar spine and proximal femur.

          4. Has a history of or currently has osteoporosis, or other metabolic bone disease,
             hyperparathyroidism, hyperprolactinemia, hyperthyroidism, anorexia nervosa, or low
             traumatic (from the standing position) or atraumatic fracture (toe, finger, skull,
             face and ankle fractures are allowed). A history of successfully treated
             hyperparathyroidism, hyperprolactinemia, or hyperthyroidism is allowed if the
             participant's bone mineral density is within normal limits.

          5. Has a history of the use of bisphosphonates, calcitonin, calcitriol, ipriflavone,
             teriparatide, denosumab, or any medication other than calcium and vitamin D
             preparations to treat bone mineral density loss.

          6. Has been a participant in an investigational drug or device study within the 1 month
             prior to the first screening visit.
Clinical trial NCT03051607 (phase 3, status: terminated)
Conditions: idiopathic parkinson disease
ICD codes: E20.0, I95.0, L50.1, D61.3, G24.2, G24.4, G60.3
Drugs: tozadenant
SMILES: COC1=C2N=C(NC(=O)N3CCC(C)(O)CC3)SC2=C(C=C1)N1CCOCC1
Reason stopped: 
    new safety information
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patient understands study requirements and has given his/her written informed consent
             on an Institutional Review Board (IRB) or Independent Ethics Committee (IEC) approved
             consent form.

          -  Parkinson's disease diagnosis consistent with UK Parkinson's Disease Society Brain
             Bank Diagnostic criteria

          -  Minimum of 3 years since diagnosis.

          -  Meet Hoehn and Yahr PD stage

          -  Good response to levodopa

          -  Stable regimen of anti-PD medications

          -  Patients must have been taking a levodopa-containing anti-PD medication continuously
             for at least the previous 12 months

          -  Patient has documented a minimum amount of Off time.

          -  If of childbearing potential (male and female) must use an acceptable method of
             contraception

        Exclusion Criteria:

          -  Previous tozadenant study participation

          -  Current or recent participation in another study.

          -  Secondary or atypical parkinsonism

          -  Neurosurgical intervention for PD (except DBS if electrode placement has been
             performed over 12 months prior to screening)

          -  Patient is taking apomorphine, budipine, istradefylline, tolcapone, or DUOPA™/Duodopa®

          -  Treatment with excluded medications

          -  Untreated or uncontrolled hyperthyroidism or hypothyroidism

          -  Clinically significant out-of-range laboratory

          -  MMSE out of range

          -  Current episode of major depression (stable treatment for depression is permitted).

          -  Recent suicide attempt or suicidal ideation type 4 or type 5 of the Columbia-Suicide
             Severity Rating Scale (C-SSRS)

          -  Women lactating or pregnant

          -  Hypersensitivity to any components of tozadenant or excipients

          -  Abnormal findings on the physical or neurological examination, or medical history that
             would make the patient unsuitable for the study

          -  History of hepatitis or cholangitis
Clinical trial NCT03053050 (phase 3, status: terminated)
Conditions: nonalcoholic steatohepatitis
ICD codes: K75.81
Drugs: sel, placebo to match sel 6 mg, placebo to match sel 18 mg
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    this study was terminated early due to lack of efficacy based on the results of the week 48
    analysis as prespecified in the clinical study protocol.
  
Eligibility criteria:

        Key Inclusion Criteria:

          -  Liver biopsy consistent with NASH and bridging (F3 fibrosis) according to the NASH
             Clinical Research Network (CRN) classification in the opinion of the central reader

          -  Has the following laboratory parameters at the screening visit:

               -  Alanine aminotransferase (ALT) ≤ 8 x upper limit of normal (ULN)

               -  Creatinine Clearance (CLcr) ≥ 30 milliliter/minute (mL/min), as calculated by the
                  Cockcroft-Gault equation

               -  Hemoglobin A1c (HbA1c) ≤ 9.5% (or serum fructosamine ≤ 381 μmol if HbA1c is
                  unable to be resulted)

               -  Total bilirubin ≤ 1.3 x ULN (unless an alternate etiology such as Gilbert's
                  syndrome or hemolytic anemia is present)

        Key Exclusion Criteria:

          -  Prior history of decompensated liver disease including clinical ascites, hepatic
             encephalopathy (HE), or variceal bleeding

          -  Child-Pugh (CP) score > 6, as determined at screening, unless due to therapeutic
             anti-coagulation

          -  Model for End-stage Liver Disease (MELD) score > 12, as determined at screening,
             unless due to therapeutic anti-coagulation

          -  Other causes of liver disease including, but not limited to, alcoholic liver disease,
             hepatitis B, hepatitis C, autoimmune disorders, drug-induced hepatotoxicity, Wilson
             disease, iron overload, and alpha-1-antitryspin deficiency, based on medical history
             and/ or centralized review of liver histology.

          -  History of liver transplantation

          -  Current or history of hepatocellular carcinoma (HCC)

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Clinical trial NCT03053063 (phase 3, status: terminated)
Conditions: nonalcoholic steatohepatitis
ICD codes: K75.81
Drugs: sel, placebo to match sel 6 mg, placebo to match sel 18 mg
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    this study was terminated early due to lack of efficacy based on the results of the week 48
    analysis as prespecified in the clinical study protocol.
  
Eligibility criteria:

        Key Inclusion Criteria:

          -  Liver biopsy consistent with NASH and cirrhosis (F4 fibrosis) according to the NASH
             Clinical Research Network (CRN) classification, in the opinion of the central reader

          -  Has the following laboratory parameters at the screening visit, as determined by the
             central laboratory:

               -  Alanine aminotransferase (ALT) ≤ 8 x upper limit of normal (ULN)

               -  Creatinine Clearance (CLcr) ≥ 30 milliliter/minute (mL/min), as calculated by the
                  Cockcroft-Gault equation

               -  HbA1c ≤ 9.5% (or serum fructosamine ≤ 381 micromole (μmol) if HbA1c is unable to
                  be resulted)

               -  International normalised ratio (INR) ≤ 1.4, unless due to therapeutic
                  anti-coagulation

               -  Platelet count ≥ 100,000/μL

        Key Exclusion Criteria:

          -  Prior history of decompensated liver disease including clinical ascites, hepatic
             encephalopathy (HE), or variceal bleeding

          -  Child-Pugh (CP) score > 7, as determined at screening, unless due to therapeutic
             anti-coagulation

          -  Model for End-stage Liver Disease (MELD) score > 12, as determined at screening,
             unless due to therapeutic anti-coagulation

          -  Other causes of liver disease including, but not limited to, alcoholic liver disease,
             hepatitis B, hepatitis C, autoimmune disorders, drug-induced hepatotoxicity, Wilson
             disease, iron overload, and alpha-1-antitrypsin deficiency, based on medical history
             and/or centralized review of liver histology.

          -  History of liver transplantation

          -  Current or history of hepatocellular carcinoma (HCC)

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Clinical trial NCT03053388 (phase 3, status: completed)
Conditions: bronchiolitis
ICD codes: J21.9, J84.115, J21.1, J21.0, J21.8
Drugs: nitric oxide
SMILES: OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C1NC=NC2=O
Eligibility criteria:

        Inclusion Criteria:

          1. 1. Pediatric subjects 0-12-months old.

             a. Including subjects born at ≥28 weeks of gestation.

          2. Subjects with acute bronchiolitis requiring in-patient hospitalization expected for 24
             hours and more.

          3. Clinical score of between 7 to 10 at Screening (without oxygen supplementation).

          4. Parent/guardian who is willing and able to sign, an informed consent on behalf of the
             subject.

        Exclusion Criteria:

          1. 1. Subjects diagnosed with alveolar pneumonia on Chest X-ray (including WBC≥
             15,000/ul, and Temp >39°C).

          2. Previous diagnosis of asthma or requirement for asthma medications.

          3. Subjects with >2 previous wheezing episodes.

          4. History of life-threatening respiratory distress that requires admission to an
             intensive care unit for treatment.

          5. Subjects with history of methemoglobinemia and/or methemoglobin >5% for any cause.

          6. Use of an investigational drug within 30 days before enrolment and/or expected to
             participate in a new study within 90 days.

          7. History of frequent epistaxis (>1 episode/month) or significant hemoptysis within 30
             days prior to enrolment (≥5 mL of blood in one coughing episode or >30 mL of blood in
             a 24-hour period.

          8. Taken medications such as chronic systemic corticosteroids, CNS stimulants,
             theophylline or aminophylline, anti-arrhythmic within a certain time period prior to
             the study.

          9. Unable to comply with the study procedures.

         10. Underlying genetic disorders (including Cystic fibrosis) or hypotonia.

         11. Having the following signs or symptoms: 1) known pulmonary (lung) and/or cardiac
             (heart) congenital malformations 2) an underlying renal, or liver insufficiency,
             immunodeficiency, encephalopathy; 3) known or suspected foreign body aspiration.

         12. Any reason that, in the opinion of the investigator, may make the subject unfit for
             this clinical trial.
Clinical trial NCT03054428 (phase 3, status: completed)
Conditions: moderate-to-severe atopic dermatitis, dermatitis, dermatitis atopic, eczema, skin diseases, skin, diseases genetic, genetic, diseases inborn, skin, disease, eczematous skin, hypersensitivity, immediate, hypersensitivity, immune system diseases, dermatitis, atopic
ICD codes: L56.2, B65.3, L13.0, L22, L26, L30.0, L30.3, L20.89, L20.9, Z14.8, Z15.89, Z84.81, Z13.71, Z31.430, Z31.440, H01.131, H01.132, H01.134, H01.135, H01.133, H01.136, H01.139, M31.0, M36.4, J39.3, J67.8, J67.9, M31.0, M36.4, J39.3, J67.8, J67.9, L20.89, L20.9
Drugs: dupilumab, placebo
SMILES: CCO, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female ≥12 to <18 years of age at time of screening visit

          -  Diagnosis of AD according to the American Academy of Dermatology consensus criteria at
             screening visit

          -  IGA ≥3 at screening and baseline visit

          -  EASI ≥16 at the screening and baseline visit

          -  Baseline Pruritus NRS average score for maximum itch intensity ≥4

          -  ≥10% BSA of AD involvement at the screening and baseline visits

          -  With documented recent history (within 6 months before the screening visit) of
             inadequate response to topical AD medication(s) or for whom topical treatments is
             medically inadvisable

        Exclusion Criteria:

          -  Participation in a prior dupilumab clinical study

          -  Treatment with topical corticosteroids (TCS) or topical calcineurin inhibitors (TCI)
             within 2 weeks before the baseline visit

          -  Having used immunosuppressive/immunomodulating drugs within 4 weeks before the
             baseline visit

          -  Body weight <30 kg at baseline

          -  Active chronic or acute infection requiring treatment with systemic antibiotics,
             antivirals, antiprotozoals, or antifungals within 2 weeks before the baseline visit

          -  Known or suspected immunodeficiency, known history of human immunodeficiency virus
             (HIV) infection or HIV seropositivity at the screening visit, established diagnosis of
             HBV infection or HBV seropositivity at screening, established diagnosis of HCV
             infection or HCV seropositivity at screening

          -  History of malignancy before the baseline visit

          -  Diagnosed active endoparasitic infections or at high risk of these infections

          -  Patient is female who is pregnant, breastfeeding, or planning to become pregnant or
             breastfeed during the study

          -  Patient is female of childbearing potential and sexually active, who is unwilling to
             use adequate methods of contraception throughout the duration of the study and for 120
             days after the last dose of study drug

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT03061812 (phase 3, status: completed)
Conditions: small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: rovalpituzumab tesirine, topotecan, dexamethasone
SMILES: CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Participant must have histologically or cytologically confirmed advanced or metastatic
             Small Cell Lung Cancer (SCLC) with documented first disease progression during or
             following front-line platinum-based systemic regimen

          -  Tumor must have high Delta-like protein 3 (DLL3) expression defined as having ≥ 75%
             tumor cells staining positive according to the VENTANA DLL3 (SP347) IHC Assay.

          -  Participant must have measurable disease, as defined per Response Evaluation Criteria
             in Solid Tumors (RECIST) version 1.1.

          -  Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status
             of 0 or 1.

          -  Participant must have recovery to Grade 0 or 1 of any clinically significant toxicity
             (excluding alopecia) prior to initiation of study drug administration.

        Exclusion Criteria:

          -  Participant has a documented history of a cerebral vascular event (stroke or transient
             ischemic attack), unstable angina, myocardial infarction, or cardiac symptoms
             consistent with New York Heart Association Class (NYHA) III - IV within 6 months prior
             to their first dose of study drug.

          -  Participant has known leptomeningeal metastases.

          -  Participant has received more than one prior systemic therapy regimen for SCLC.

          -  Participant had a serious infection within 2 weeks prior to randomization, including
             any Grade 3 or higher viral, bacterial, or fungal infection.

          -  Participant has a history of active malignancies other than SCLC within the past 2
             years prior to study entry, with the exception of in situ cancer which was curatively
             treated.

          -  Participant had prior exposure to topotecan, irinotecan or any other topoisomerase I
             inhibitors.
Clinical trial NCT03066609 (phase 3, status: completed)
Conditions: plaque psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: secukinumab 150 mg s.c., secukinumab 300 mg s.c., placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Subjects must give a written, signed and dated informed consent.

          2. Men or women at least 18 years of age at time of screening.

          3. Chronic plaque-type psoriasis present for at least 6 months and diagnosed before
             Baseline.

          4. Moderate to severe psoriasis as defined at Baseline by:

               -  PASI score of 12 or greater, and

               -  IGA mod 2011 score of 3 or greater (based on a static scale of 0 - 4), and

               -  Body Surface Area (BSA) affected by plaque-type psoriasis of 10% or greater.

          5. Candidate for systemic therapy. This is defined as a subject having moderate to severe
             chronic plaque-type psoriasis that is inadequately controlled by

               -  topical treatment and/or,

               -  phototherapy and/or,

               -  previous systemic therapy.

        Exclusion Criteria:

          1. Forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic and
             guttate psoriasis) at Screening or Baseline.

          2. Drug-induced psoriasis.

          3. Ongoing use of prohibited treatments.

          4. Previous exposure to secukinumab (AIN457) or any other biologic drug directly
             targeting IL-17 or the IL-17 receptor.

          5. Use of other investigational drugs at the time of enrollment, or within 5 half-lives
             of enrollment, or within 30 days until the expected pharmacodynamic effect has
             returned to baseline, whichever is longer; or longer if required by local regulations.

          6. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a
             female after conception and until the termination of gestation, confirmed by a
             positive hCG laboratory test.